ArticleMycoses2021
Molecular identification and antifungal susceptibility profiles of Candida dubliniensis and Candida africana isolated from vulvovaginal candidiasis: A single-centre experience in Iran.
Article in Mycoses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Antifungal and Antivirulence Activity of Alizarin againstACS infectious diseases · 2026Article
- Species Distribution, Characterization, and Antifungal Susceptibility Patterns ofAntibiotics (Basel, Switzerland) · 2025Article
- HWP1 Gene Sequence Diversity and Antifungal Susceptibility Patterns in Colombian Vulvovaginal Isolates of theInternational journal of microbiology · 2025Article
- Reported prevalence and comparison of diagnostic approaches for Candida africana: a systematic review with meta-analysis.Diagnostic and prognostic research · 2024Review
- Analysis of Whole-Genome facilitates rapid and precise identification of fungal species.Frontiers in microbiology · 2024Article
- Molecular Testing for the Diagnosis of Bacterial Vaginosis.International journal of molecular sciences · 2023Review
- Prevalence of Closely RelatedPolish journal of microbiology · 2023Article
- Candida dubliniensis fungemia in a patient with severe COVID-19: A case report.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2022Article
- Article
- Molecular discrimination and antifungal susceptibility profile of crypticIranian journal of microbiology · 2022Article
- Otomycosis in the South of Iran with a High Prevalence of Tympanic Membrane Perforation: A Hospital-Based Study.Mycopathologia · 2022Review
- Epidemiology, prevalence, and associated factors of oral candidiasis in HIV patients from southwest Iran in post-highly active antiretroviral therapy era.Frontiers in microbiology · 2022Article
- Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis.Frontiers in immunology · 2022Article
- Article
- Differentiation ofCurrent medical mycology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundVulvovaginal candidiasis (VVC) is a common and debilitating long-term illness affecting million women worldwide. This disease is caused mainly by Candida albicans and a lesser extent by other species, including the two phylogenetically closely related pathogens Candida africana and Candida dubliniensis.
objectivesIn this study, we report detailed molecular epidemiological data about the occurrence of these two pathogenic yeasts in Iranian patients affected by VVC, or its chronic recurrent form (RVVC), and provide, for the first time, data on the antifungal activity of two new drugs, efinaconazole (EFN) and luliconazole (LUL).
methodsA total of 133 vaginal yeast isolates, presumptively identified as C albicans by phenotypic and restriction analysis of rDNA, were further analysed by using a specific molecular method targeting the HWP1 gene. All C africana and C dubliniensis isolates were also tested for their in vitro susceptibility to a panel of modern and classical antifungal drugs. RESULTS AND
conclusionsBased on the molecular results, among 133 germ-tube positive isolates, we identify 119 C albicans (89.47%), 11 C africana (8.27%) and 3 C dubliniensis (2.26%) isolates. C africana and C dubliniensis showed low MIC values for most of the antifungal drugs tested, especially for EFN and LUL, which exhibited a remarkable antifungal activity. High MIC values were observed only for nystatin and terbinafine. Although C albicans remains the most common Candida species recovered from Iranian VVC/RVVC patients, our data show that its prevalence may be slightly overestimated due to the presence of difficult-to-identify closely related yeast, especially C africana.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.